Pages that link to "Q117835529"

The following pages link to Edith Monteagudo (Q117835529):

Displaying 44 items.

• Discovery and Characterization of Novel Anti-schistosomal Properties of the Anti-anginal Drug, Perhexiline and Its Impact on Schistosoma mansoni Male and Female Reproductive Systems (Q28553478) (← links)
• MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants (Q34276394) (← links)
• Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor (Q34423056) (← links)
• Discovery of a Selective Series of Inhibitors of Plasmodium falciparum HDACs (Q36902765) (← links)
• Synthesis, biological evaluation, and molecular modeling studies of rebeccamycin analogues modified in the carbohydrate moiety (Q38295005) (← links)
• An efficient liquid chromatography-high resolution mass spectrometry approach for the optimization of the metabolic stability of therapeutic peptides. (Q38990711) (← links)
• Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide (Q39063782) (← links)
• Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors (Q39782128) (← links)
• Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties (Q39851679) (← links)
• A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo (Q39997836) (← links)
• Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors (Q40020942) (← links)
• Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable N-methyl pyrimidones (Q40083647) (← links)
• Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors (Q40146937) (← links)
• Use of 'dilute-and-shoot' liquid chromatography-high resolution mass spectrometry in preclinical research: application to a DMPK study of perhexiline in mouse plasma. (Q40374696) (← links)
• Synthesis and antiviral properties of novel 7-heterocyclic substituted 7-deaza-adenine nucleoside inhibitors of Hepatitis C NS5B polymerase (Q42717071) (← links)
• ApoA-I mimetic peptides promote pre-β HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher dose (Q42790649) (← links)
• Novel macrocyclic inhibitors of hepatitis C NS3/4A protease featuring a 2-amino-1,3-thiazole as a P4 carbamate replacement (Q42992090) (← links)
• Enhancement of intestinal absorption of 2-methyl cytidine prodrugs (Q43127840) (← links)
• Turbulent flow chromatography TFC-tandem mass spectrometry supporting in vitro/vivo studies of NCEs in high throughput fashion (Q43246709) (← links)
• High-throughput microsomal stability assay for screening new chemical entities in drug discovery (Q43655654) (← links)
• Quantitative prediction of human clearance guiding the development of Raltegravir (MK-0518, isentress) and related HIV integrase inhibitors (Q45751131) (← links)
• A novel strategy for reducing phospholipids-based matrix effect in LC-ESI-MS bioanalysis by means of HybridSPE. (Q45954465) (← links)
• HILIC LC-MS for the determination of 2'-C-methyl-cytidine-triphosphate in rat liver (Q46060545) (← links)
• Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection (Q46396658) (← links)
• Conformations of laulimalide in DMSO-d6. (Q46700532) (← links)
• High sensitivity determination of valproic acid in mouse plasma using semi-automated sample preparation and liquid chromatography with tandem mass spectrometric detection (Q46813695) (← links)
• PEGylation of Neuromedin U yields a promising candidate for the treatment of obesity and diabetes (Q47410449) (← links)
• A single-run liquid chromatography mass spectrometry method to quantify neuroactive kynurenine pathway metabolites in rat plasma (Q48335453) (← links)
• Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclo- propyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydro-imidazo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies (Q51861701) (← links)
• Enhanced mass resolution method development, validation and assay application to support preclinical studies of a new drug candidate (Q51945710) (← links)
• Determination of acetyl coenzyme A in human whole blood by ultra-performance liquid chromatography-mass spectrometry. (Q52663080) (← links)
• Fosmetpantotenate (RE-024), a phosphopantothenate replacement therapy for pantothenate kinase-associated neurodegeneration: Mechanism of action and efficacy in nonclinical models. (Q52664420) (← links)
• DPP‐IV‐resistant, long‐acting oxyntomodulin derivatives (Q53270212) (← links)
• MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants. (Q55430061) (← links)
• The synthesis of tetrahydropyridopyrimidones as a new scaffold for HIV-1 integrase inhibitors (Q60455448) (← links)
• 4,5-dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical species (Q79416335) (← links)
• Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells (Q82294446) (← links)
• N-(2-alkylaminoethyl)-4-(1,2,4-oxadiazol-5-yl)piperazine-1-carboxamides as highly potent smoothened antagonists (Q84624373) (← links)
• A liquid chromatography high-resolution mass spectrometry in vitro assay to assess metabolism at the injection site of subcutaneously administered therapeutic peptides (Q90444913) (← links)
• A novel method using nuclear magnetic resonance for plasma protein binding assessment in drug discovery programs (Q91433915) (← links)
• Establishment of an in Vitro Human Blood-Brain Barrier Model Derived from Induced Pluripotent Stem Cells and Comparison to a Porcine Cell-Based System (Q92120751) (← links)
• Application of an in Vitro Blood-Brain Barrier Model in the Selection of Experimental Drug Candidates for the Treatment of Huntington's Disease (Q92651187) (← links)
• Synthesis and Biological Evaluation of RGD⁻Cryptophycin Conjugates for Targeted Drug Delivery (Q92794475) (← links)
• Improved Selective Class I HDAC and Novel Selective HDAC3 Inhibitors: Beyond Hydroxamic Acids and Benzamides (Q93166653) (← links)